Ars TechnicaCenter·
Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial
The interim Phase I trial data was only from 35 people, but results look good so far.
Read at Ars Technica →
Technology · 1 sources covering this
Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial
The interim Phase I trial data was only from 35 people, but results look good so far.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/c370ce15bb0678d7f49e0b1b4cc36f1cdfe93d55" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial"></iframe>
